Grant McArthur

γδ T cells in Merkel cell carcinomas have a proinflammatory profile prognostic of patient survival.

Nicholas A Gherardin, Kelly Waldeck, Alex Caneborg, Luciano G Martelotto, Shiva Balachander, Magnus Zethoven, Pasquale M Petrone, Andrew Pattison, James S Wilmott, Sergio M Quiñones-Parra, Fernando Rossello, Atara Posner, Annie Wong, Alison M Weppler, Kerwin F Shannon, Angela Hong, Peter M Ferguson, Valerie Jakrot, Jeanette Raleigh, Athena Hatzimihalis, et al.

Journal article  |  2021  |  Cancer Immunology Research

Merkel cell carcinomas (MCC) are immunogenic skin cancers associated with viral infection or UV-mutagenesis. To study T-cell infil..

Evolution of late-stage metastatic melanoma is dominated by aneuploidy and whole genome doubling.

Ismael A Vergara, Christopher P Mintoff, Shahneen Sandhu, Lachlan McIntosh, Richard J Young, Stephen Q Wong, Andrew Colebatch, Daniel L Cameron, Julia Lai Kwon, Rory Wolfe, Angela Peng, Jason Ellul, Xuelin Dou, Clare Fedele, Samantha Boyle, Gisela Mir Arnau, Jeanette Raleigh, Athena Hatzimihalis, Pacman Szeto, Jennifer Mooi, et al.

Journal article  |  2021  |  Nature Communications

Although melanoma is initiated by acquisition of point mutations and limited focal copy number alterations in melanocytes-of-origi..

Decline in cancer pathology notifications during the 2020 COVID-19-related restrictions in Victoria

Luc te Marvelde, Rory Wolfe, Grant McArthur, Louis A Blake, Sue M Evans

Journal article  |  2021  |  The Medical Journal of Australia

An inverse stage-shift model to estimate the excess mortality and health economic impact of delayed access to cancer services due to the COVID-19 pandemic

Koen Degeling, Nancy N Baxter, Jon Emery, Mark A Jenkins, Fanny Franchini, Peter Gibbs, G Bruce Mann, Grant McArthur, Benjamin J Solomon, Maarten J IJzerman

Journal article  |  2021  |  Asia-Pacific Journal of Clinical Oncology

AIM: Decreased cancer incidence and reported changes to clinical management indicate that the COVID-19 pandemic has delayed cancer..

CDK4/6 Inhibition Reprograms Mitochondrial Metabolism in BRAF(V600) Melanoma via a p53 Dependent Pathway

Nancy T Santiappillai, Shatha Abuhammad, Alison Slater, Laura Kirby, Grant A McArthur, Karen E Sheppard, Lorey K Smith

Journal article  |  2021  |  Cancers

Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are being tested in numerous clinical trials and are currently employed succes..

Combined BRAF, MEK, and CDK4/6 Inhibition Depletes Intratumoral Immune-Potentiating Myeloid Populations in Melanoma

Emily J Lelliott, Stefano Mangiola, Kelly M Ramsbottom, Magnus Zethoven, Lydia Lim, Peter KH Lau, Amanda J Oliver, Luciano G Martelotto, Laura Kirby, Claire Martin, Riyaben P Patel, Alison Slater, Carleen Cullinane, Anthony T Papenfuss, Nicole M Haynes, Grant A McArthur, Jane Oliaro, Karen E Sheppard

Journal article  |  2021  |  Cancer Immunology Research

Combined inhibition of BRAF, MEK, and CDK4/6 is currently under evaluation in clinical trials for patients with melanoma harboring..

Management of melanoma brain metastases: Evidence-based clinical practice guidelines by Cancer Council Australia

Angela M Hong, Cora Waldstein, Brindha Shivalingam, Matteo S Carlino, Victoria Atkinson, Richard F Kefford, Grant A McArthur, Alexander M Menzies, John F Thompson, Georgina Long

Journal article  |  2021  |  European Journal of Cancer

Reprogrammed mRNA translation drives resistance to therapeutic targeting of ribosome biogenesis

Eric P Kusnadi, Anna S Trigos, Carleen Cullinane, David L Goode, Ola Larsson, Jennifer R Devlin, Keefe T Chan, David P De Souza, Malcolm J McConville, Grant A McArthur, George Thomas, Elaine Sanij, Gretchen Poortinga, Ross D Hannan, Katherine M Hannan, Jian Kang, Richard B Pearson

Journal article  |  2020  |  The EMBO Journal

Elevated ribosome biogenesis in oncogene-driven cancers is commonly targeted by DNA-damaging cytotoxic drugs. Our previous first-i..

ASSOCIATION OF RESPONSE WITH SURVIVAL OUTCOMES WITH ATEZOLIZUMAB IN COMBINATION WITH VEMURAFENIB AND COBIMETINIB IN THE PHASE 3 IMSPIRE150 STUDY

Paolo Ascierto, Karl Lewis, Caroline Robert, Daniil Stroyakovskiy, Helen Gogas, Svetlana Protsenko, Rodrigo Pereira, Thomas Eigentler, Piotr Rutkowski, Lev Demidov, Georgy Moiseevich Manikhas, Haocheng Li, Qian Zhu, Edward McKenna, Virginia McNally, Ralf Gutzmer, Grant McArthur

Conference Proceedings  |  2020  |  Journal for ImmunoTherapy of Cancer

ATEZOLIZUMAB PLUS VEMURAFENIB AND COBIMETINIB PROVIDES FAVORABLE SURVIVAL OUTCOMES IN PATIENTS WITH HIGH TUMOR MUTATION BURDEN AND PROINFLAMMATORY GENE SIGNATURE IN THE PHASE 3 IMSPIRE150 STUDY

Karl Lewis, Paolo Ascierto, Caroline Robert, Rodrigo Munhoz, Gabriella Liszkay, Luis De La Cruz Marino, Judit Olah, Paola Queirolo, Jacek Mackiewicz, Kalpit Shah, Harper Forbes, Christian Hertig, Yibing Yan, Ralf Gutzmer, Grant McArthur

Conference Proceedings  |  2020  |  Journal for ImmunoTherapy of Cancer